Get started

Cloverhealth

Clover Health Will Show A Technical Growth In Channel To $9.92After a false breakout due to a correction in the broader market, $CLOV has re-entered the falling channel it has broken out of and closed within it. From this area, I expect growth towards the resistance zone around $9.92 to $10.00. However, do note that this zone of resistance that we are heading for is a very strong area of resistance. In this area, we see an intersection of: 1. Dynamic resistance created by the upper parallel line of the falling channel 2. Fibonacci resistance and Horizontal resistance 3. Former $10 SPAC price floor which acts as a very strong psychological resistance Regardless, I expect a move towards it first. Would have to see how the market reacts to this level first before deciding on our next course of action. This is not an investment or trading advice so please do your own due diligence! Support this idea with likes and share your thoughts below.
NASDAQ:CLOVLong
by AntrePoint
1
Clover Health Continues To Track The Broader Market Very CloselySince the market started selling-off late February due to disturbance in the bond market, the movements of $CLOV has since been mirroring the direction of the overall market relatively tightly. With the closing of the market earlier today after a considerably sideway and mixed trading day, S&P 500 rose by 0.60%, NASDAQ fell by 0.04%, while Dow Jones Industrial Average rose by 1.46%. Similarly, $CLOV also had a relatively mixed trading day, showing green for the first half of the trading session, and later closing slightly red on the second half. These movements can be attributed to the general market condition as well, where during the first half of the trading session, the release of bullish CPI data edged the market higher, while a relatively average and within expectations $38 billion 10-year notes auction brought the action back down to trade relatively sideway. I expect $CLOV to continue tracking the overall direction of the market closely, at least for tomorrow, where we await for the result of a $24 billion sale of 30-year bond that can potentially move the market significantly in either direction, should anything unexpected occur. Regardless, it is good to note that on a technical perspective, $CLOV is approaching some key trading area that we need to take note of. We are currently resting just below the dynamic resistance formed by the bottom of the previous bearish channel that were trading in before this bond-induced market correction. While we may have already rejected this area once (likely due to the broader market movement as mentioned above), if we are able to break back into the bearish channel, our next target would be the next Fibonacci resistance and the top of the aforementioned bearish channel at around $9.92. However, if we fail to break back into it, we could be looking at a re-test of $7.78 or even $6.67. As such, tomorrow's trading session will likely be a very important one as it will give us an indication of where we are headed short-term. Invest safe. This is not investment advice so please do your own due diligence! Support this idea with likes and share your thoughts below.
NASDAQ:CLOVLong
by AntrePoint
Clover Health Rallies Despite An Early Sell-off Into A $6.31 LowThe movement of $CLOV continues to mirror the condition of the overall market. Today, the tech-led sell-off took a pause, with S&P 500 rising by 1.95% and NASDAQ Composite rising by 1.55%. Similarly, Clover Health ended higher by 7.54%, closing above the previous day's close. Going into next week, I expect $CLOV performance to continue reflecting the overall market condition. Nevertheless, these are some notable resistance and support area that you should take note next week, with key areas highlighted in Bold: Psychological resistance: $8.00 , $8.50 , $9.00 Psychological support: $7.50, $7.00, $6.50 , $6.00 Fibonacci resistance: $9.92 Fibonacci support: $7.78, $6.67 , $5.07 Dynamic resistance: Bottom of the previous bearish channel that we were trading in before this market correction ( ~$8.50 ) Dynamic support: Top of the very tight bearish channel that we just broke out of (~$7.10) Once this correction is over, I expect $CLOV to emerge as one of the winners. Invest safe. This is not investment advice so please do your own due diligence! Support this idea with likes and share your thoughts below.
NASDAQ:CLOVLong
by AntrePoint
6
$CLOV Finding The BottomThe bearish channel has broken to the downside and we are now in an unchartered territory. Within this unchartered territory, I expect every $0.50 to be a new support (i.e. $8.50, $8.00, $7.50, $7.00, and so on). As of the time that I am writing this post, we have broken the $8.50 support and found a $8.03 low. It will be difficult to predict where we will find a bottom, but what I can tell you is that $CLOV is severely undervalued at this price. It was undervalued at $10, it is undervalued at $8.00, and it will still be undervalued if it dips below $8.00. $CLOV recent earnings, albeit slower than expected, has proved that it is capable of growth. This will be a winner further down the road. However, if you are in this for a quick buck, $CLOV is not for you. But if you are an investor, do your fullest DD, strengthen your resolves, and buckle your seatbelts, because you are in for a rollercoaster ride until the negative sentiment surrounding $CLOV settles down. Regardless, $CLOV will be a winner for long-term investors. Chamath Palihapitiya once said in a CNBC interview that Clover Health will be their next 10x in 10 years investment, and I truly believe $CLOV is capable of it. This is not investment advice so please do your own due diligence! Support this idea with likes and share your thoughts below.
NASDAQ:CLOVLong
by AntrePoint
$CLOV Earnings OutlookFrom 2019 to 2020, $CLOV posted a total revenue growth from $462.3M to $672.9M, net premium revenue growth from $456.9M to $665.7M, decrease in net loss from -$363.7M to -$91.6M, and a decrease in adjusted EBITDA loss from -$175.5M to -$74.4M, among others. $CLOV also saw a 36.3% increase in membership and a 43.2% year-over-year increase in lives under Clover Assistant management to 58,056 membership and over 32,400 lives respectively. For full year 2021 guidance, $CLOV stated a total revenue expectation of $820M to $850M, net loss expectation of -$210M to -$170M, adjusted EBITDA loss expectation of -$190M to -$150M, loss per share of -$0.52 to -$0.42. Furthermore, they are also expecting a 17% to 21% growth in Medicare Advantage membership to 68,000 to 70,000 membership compared to year end 2020's 58,056. Based on the above full year 2020 financial results and full year 2021 guidance reported by Clover Health, I believe it puts us somewhere in the middle of our bear case and base case as said according to our last $CLOV Bear Base Bull outlook, which you can re-visit by looking at the related idea below. In my opinion, despite being off-target, the financial and membership growth that they have posted from 2019 to 2020 has demonstrated their ability to deliver growth, proven the scalability of their business model, and reaffirmed Chamath Palihapitiya statement of $CLOV having a predictable growth model. However, I believe they have shot themselves in their foot with the full year 2021 guidance. Based on the figures they have posted, it tells me that they are expecting a slowdown in growth compared to what they have experienced from 2019 to 2020. This will not be viewed kindly by investors and Wall Street. Going forward, I expect $CLOV to continue trading within the bearish channel, within the range of $8.50 to $10.50. Unless further positive catalyst appears, I do not see $CLOV breaking above the bearish channel yet. Nevertheless, in an environment where many SPAC and companies are trading at a massive speculative values, I see $CLOV being valued realistically at the moment and trading at a realistic price. Once given enough time to play out the growth that $CLOV is currently building, it will be a long-term winner. TLDR: Short-term: Underperform with a trading range of $8.50 to $10.50 unless more positive catalyst appears, Mid/Long-term: Easily >2x from current price. This is not investment advice so please do your own due diligence! Support this idea with likes and share your thoughts below.
NASDAQ:CLOVLong
by AntrePoint
7
$CLOV Bear Base Bull Outlook$CLOV continues to move within the symmetrical triangle while being encapsulated by a bearish channel. As we approach the end of the symmetrical triangle, I am expecting a breakout to by next week, as early as Monday. I believe the upcoming earnings on 03/01/2021's post-market to be a major catalyst to which direction the breakout will be. Bear Case: In the event that we get a negative earnings surprise, $CLOV will be headed further down into unchartered territory. The sell-off will likely be exacerbated by weakening market conditions and the lack of PR by Chamath Palihapitiya, Vivek Garipalli, and Clover Health Corp. Throw in the FUD created by the Hidenburg Research's short-seller report, and you have a recipe for a sell-off into the $7 and $8 territory. How soon we recovery from that will likely depend on the impact of the fiscal stimulus, whether there are any positive news released by Clover/Chamath/Vivek, and how long it takes for the short-seller report to be cleared up by the SEC. Base Case: Earnings data come out as expected and there was no deviation compared to what was expected. Due to technical factors such as RSI pointing towards $CLOV being incredibly oversold, volume picking up again, and $CLOV currently being in an area of multiple huge support level, we see a push back to the dynamic resistance of the bearish channel. However, breaking above could prove to be challenging without positive sentiments around $CLOV. We might start consolidating between $10 to $11 or even re-test the dynamic support of the bearish channel. Bull Case: Clover Health Corp releases a positive earnings surprise and Clover/Chamath/Vivek takes the opportunity to boost PR to create more positive sentiments around $CLOV. The aforementioned, supported by bullish technical indicators, pushes $CLOV back to the dynamic resistance of the bearish channel, subsequently breaking beyond it and holding above the bearish channel. As the fiscal stimulus comes in, we see money flowing into the stock market, and $CLOV continue to grow towards $14 and beyond. TLDR: $7-$8 Bear Case, $10-$11 Base Case, >$14 Bull Case. This is not investment advice so please do your own due diligence! Support this idea with likes and share your thoughts below.
NASDAQ:CLOVLong
by AntrePoint
6
$CLOV Stick to the PlanTrue longs are staying patient, even with the volatile week we've experienced thus far. $CLOV is attempting to make a presence within the healthcare industry, which is never an easy path. Their mission as a company will be very difficult to pursue, although a very lucrative one if executed adequately. With a Biden Administration advocating health care for all in America, the push from various lawmakers in congress will help aid individuals gain access to companies like Clover, who are offering insurance at very little-to-none premiums, copays, and prescription drug prices. I will be updating this post as I have entered a multi-week swing, which may turn into a long-term hold- depending on confirmation within the price action. GLTA!
NASDAQ:CLOVLong
by ClargyInvesting
1